Market researchClosed
ATNAA
DEPT OF DEFENSE › DEFENSE LOGISTICS AGENCY › DLA TROOP SUPPORT
Response deadlineOct 1, 2026 11:59 PM EDT
View official notice on SAM.gov (opens in a new tab)
Verify before acting. Users must verify deadlines, amendments, attachments, eligibility, and submission requirements on the official SAM.gov notice. Read the Data Disclaimer.
Key decision factors
- Response deadline
- Oct 1, 2026 11:59 PM EDT
- Posted
- Sep 17, 2026 12:00 AM EDT
- Notice type
- Sources Sought
- Set-aside
- No Set aside used
- PSC
- 6505 — Drugs and Biologicals
- Place of performance
- Philadelphia, Pennsylvania
- Current status
- Closed
Notice details
- Official status
- Closed
- Normalized group
- Market research
- Notice ID
- 76ace4ad60f04dfda3210032a8e5b4cf
- Solicitation number
- SPE2DP-26-D-0001
Description
Displayed as sanitized plain text from SAM.gov. Retrieved Sep 18, 2026 10:23 PM EDT.
Antidote Treatment Nerve Agent Auto-Injector Request For Information (RFI) This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL NSN: 6505-01-362-7427 Description: The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). The ATNAA shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration. Must have FDA approval to sell the ATNAA. If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
Attachments
No attachments were reported for this notice. MaroNest reflects only what the source data reports — review the official SAM.gov notice (opens in a new tab) to confirm whether related documents or amendments exist.
Contacts
Personalized relevance
Would this fit your company?
Create company profile information with a free account to see a deterministic, explainable relevance score. Matching does not determine eligibility or win probability.
Create Free AccountPursuit risk (separate from your match score)
No major pursuit restriction detected
We did not detect a major source or competition restriction in the information analyzed. This is not an eligibility determination.
Pursuit risk is evaluated separately from your match score above and never changes it. This is not a legal or eligibility determination — verify against the official SAM.gov notice and attachments.